✦ LIBER ✦

A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A

✍ Scribed by Mirte M. Malingré; Jos H. Beijnen; Hilde Rosing; Franciska J. Koopman; Olaf van Tellingen; Ken Duchin; Wim W. Ten Bokkel Huinink; Martha Swart; Jan Lieverst; Jan H.M. Schellens

Publisher: Springer
Year: 2001
Tongue: English
Weight: 114 KB
Volume: 47
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800000226

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of chronic daily dosing

A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer

✍ Masahiro Fukuoka; Noriyuki Masuda; Shunichi Negoro; Minoru Takada; Shinzoh Kudoh 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 2 views

A phase II/pharmacokinetic trial of high

A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel

✍ S. Aebi; T. W. Schnider; G. Los; D. D. Heath; D. Darrah; S. Kirmani; E. F. McCla 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 105 KB

Oral vinorelbine/paclitaxel combination

Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study

✍ R. Delva; T. Pienkowski; N. Tubiana; U. Vanhoefer; B. Longerey; I. Douville 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 282 KB

Novel paclitaxel formulations for oral a

Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours

✍ S. A. Veltkamp; H. Rosing; A. D. R. Huitema; M. R. Fetell; A. Nol; J. H. Beijnen 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

A phase I dose escalation and pharmacoki

A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors

✍ E. Gabriela Chiorean; Srikar Malireddy; Anne E. Younger; David R. Jones; Mary-Ja 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 233 KB

A phase I study of sequential administra

A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors

✍ Caio M. S. Rocha Lima; Carlo V. Catapano; Daniel Pacheco; Carol A. Sherman; Greg 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

## Abstract ## BACKGROUND Based on preclinical findings and on the clinical antitumor efficacy of sequential paclitaxel/topotecan and topotecan/etoposide, the authors sought to define the maximum tolerated doses (MTDs) and dose‐limiting toxicities (DLTs) associated with a sequential combination of